Partillion Bioscience has developed a nanovial platform that enables the rapid compartmentalization and analysis of millions of single cells to investigate biological functions, such as secreted proteins. This technology addresses the challenge of high costs and inefficiencies in traditional single-cell assays, allowing researchers to screen up to one million cells per experiment without the need for new equipment.
Funding
$9.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional single-cell assays are often expensive and inefficient, limiting researchers' ability to rapidly analyze millions of cells and investigate biological functions like secreted proteins. Existing methods may also require specialized equipment, increasing the barrier to entry for many labs.
Solution
Partillion Bioscience offers a nanovial platform designed for rapid compartmentalization and analysis of single cells, enabling researchers to screen up to one million cells per experiment using existing lab equipment. The platform utilizes biotinylated nanovials to capture and isolate individual cells, facilitating the study of secreted proteins and other biological functions. This approach significantly reduces the cost per cell compared to legacy and microfluidic methods, while maintaining cell viability for downstream experiments. Partillion's technology supports a range of applications, including antibody discovery, multicell assays, and extracellular vesicle analysis, providing a flexible solution for functional single-cell biology research.
Target Audience
Partillion Bioscience serves researchers in immunology, cell therapy, and antibody discovery, as well as pharmaceutical companies and academic institutions seeking to improve single-cell analysis workflows.
Features
- Biotinylated nanovials for efficient single-cell compartmentalization
- Compatibility with standard laboratory equipment, eliminating the need for new capital investments
- High-throughput screening of 10,000 to 1,000,000 cells per experiment
- Preserved cell viability, enabling downstream analysis such as transcriptomics
- SEC-seq (secreted protein and transcriptome sequencing) to associate molecular signatures with antibody secretion
- Antibody discovery kits for identifying high-affinity monoclonal antibodies
- Custom and bulk ordering options for tailored experimental needs